Aprea Therapeutics, Inc. (APRE) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-17

Aprea Therapeutics, Inc. (APRE) has filed 8 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-17. 2 Form 8-K material event filings were reported by APRE in the last 90 days. InsiderAlpha tracks every APRE SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Aprea Therapeutics, Inc. (APRE)

SEC CIK	0001781983

90-Day SEC Filing Activity

Form 4 filings (90d)	8
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-06-17

Recent APRE Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-16	Seizinger Bernd R.	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	Grissinger Michael	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	HENNEMAN JOHN B III	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	Peters Richard	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	Gruia Gabriela	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	Pamukcu Rifat	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	Duey Marc	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-06-16	BIZZARI JEAN-PIERRE	Director	A — Grant or award	3.1K	$0.00	—	SEC
2026-03-12	Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	A — Grant or award	10.1K	$0.00	—	SEC
2026-03-12	Gilad Oren	President/CEO	A — Grant or award	20.2K	$0.00	—	SEC
2026-01-30	Gilad Oren	President/CEO	P — Open-market purchase	28.1K	$0.89	$25K	SEC
2026-01-30	Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	P — Open-market purchase	5.7K	$0.89	$5K	SEC
2025-06-05	HENNEMAN JOHN B III	Director	A — Grant or award	1.0K	$0.00	—	SEC
2024-10-23	Gilad Oren	President/CEO	P — Open-market purchase	500	$3.92	$2K	SEC
2024-10-18	Duey Marc	Director	S — Open-market sale	6.5K	$4.58	$30K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Aprea Therapeutics, Inc. (APRE). Updated in real time as new filings are submitted to the SEC.

Most-Active APRE Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Peters Richard	2	—
Gruia Gabriela	2	—
HENNEMAN JOHN B III	2	—
Seizinger Bernd R.	2	—
Duey Marc	2	—

Recent APRE Form 8-K Material Events

2026-06-17 — Item 5.07 [SEC]
2026-05-13 — Item 2.02, 8.01, 9.01 [SEC]
2026-04-01 — Item 7.01, 9.01 · Financing · neutral [SEC]
Aprea Therapeutics closed a previously announced private placement on April 1, 2026, raising approximately $30 million in gross proceeds. This is an administrative closing announcement of a financing that was already disclosed earlier.
2026-03-30 — Item 1.01, 3.02, 7.01, 8.01, 9.01 · Financing · mixed [SEC]
Aprea Therapeutics entered into a securities purchase agreement on March 30, 2026 to issue pre-funded warrants and common stock warrants to accredited investors, with expected gross proceeds of approximately $30 million. The private placement is expected to close on March 31, 202
2026-03-16 — Item 2.02, 8.01, 9.01 · Earnings · neutral [SEC]
Aprea Therapeutics announced its financial results for Q4 2025 and full year 2025, along with an operational update. The company also updated its corporate presentation materials. No specific beat/miss language or guidance changes are evident from the filing header.

Recent Insider Filings

2026-06-17 — Grissinger Michael (Director)
2026-06-17 — Gruia Gabriela (Director)
2026-06-17 — Peters Richard (Director)
2026-06-17 — HENNEMAN JOHN B III (Director)
2026-06-17 — BIZZARI JEAN-PIERRE (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in APRE insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

APRE Insider Trading — FAQ

What is the latest insider trade for APRE?: Aprea Therapeutics, Inc. (APRE) had 8 insider filings in the last 90 days, with the most recent on 2026-06-17. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying APRE stock?: 0 insider purchases of APRE were filed in the last 90 days.
How many insiders are selling APRE stock?: 0 insider sales of APRE were filed in the last 90 days.
Where can I see APRE SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every APRE SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live APRE dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.